Influence of coagulation factors on intrinsic thrombin generation

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 1, 2007, Pages 67-71

  Stief, Thomas W ^a   Otto, Stefanie ^a   Renz, Harald ^a  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

Author keywords

Antithrombin III; Factor II; Factor IX; Factor VIII; Intrinsic coagulation activity assay; Thrombin

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN; THROMBIN;

ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; BLOOD SAMPLING; HUMAN; INTRINSIC COAGULATION ACTIVITY ASSAY; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; THROMBIN TIME;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; FIBRINOGEN; HUMANS; SENSITIVITY AND SPECIFICITY; THROMBIN;

EID: 33845726158     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32801297cd     Document Type: Article

References (17)

1. Stief TW. Specific determination of plasmatic thrombin activity. Clin Appl Thromb Hemost 2006; 12:324-329.
2. Stief TW, Otto S, Renz H. The intrinsic coagulation activity assay. Blood Coagul Fibrinolysis 2006; 17:369-378.
3. Bajaj SP, Joist JH. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy. Semin Thromb Hemost 1999; 25:407-418.
4. Hemker HC, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74:134-138.
5. al Dieri R, Alban S, Beguin S, Hemker HC. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time. J Thromb Haemost 2004; 2:1395-1401.
6. Hemker HC, Al Dieri R, Beguin S. Thrombin generation assays: accruing clinical relevance. Curr Opin Hematol 2004; 11:170-175.
7. Matsumoto T, Shima M, Takeyama M, Yoshida K, Tanaka I, Sakurai Y, et al. The measurement of low levels of factor VIII or factor IX in hemophilia A and hemophilia B plasma by clot waveform analysis and thrombin generation assay. J Thromb Haemost 2006; 4:377-384.
8. Brophy DF, Martin EJ, Gehr TW, Best AM, Paul K, Carr ME Jr. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006; 4:372-376.
9. Dargaud Y, Beguin S, Lienhart A, Al Dieri R, Trzeciak C, Bordet JC, et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93:475-480.
10. Stassen JM, Arnout J, Deckmyn H. The hemostatic system. Curr Med Chem 2004; 11:2245-2260.
11. Ofosu FA, Liu L, Freedman J. Control mechanisms in thrombin generation. Semin Thromb Hemost 1996; 22:303-308.
12. Stief TW. The fibrinogen function turbidimetric assay (FIFTA). Clin Appl Thromb Hemost (in press).
13. 2 test: the corrected chi-square comparison against the control-mean. Clin Appl Thromb Hemost (in press).
14. Mosesson MW. Antithrombin I Inhibition of thrombin generation in plasma by fibrin formation. Thromb Haemost 2003; 89:9-12.
15. Lippi G, Salvagno GL, Montagnana M, Guidi GC. Reliability of the thrombin-generation assay in frozen-thawed platelet-rich plasma. Clin Chem 2006; 52:1827-1828.
16. Stief TW. Pre-analytical coagulation alteration. Blood Coagul Fibrinolysis (in press).
17. Rai R, Sprengeler PA, Elrod KC, Young WB. Perspectives on factor Xa inhibition. Curr Med Chem 2001; 8:101-119.